Compare CRSP Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
| CRSP CRISPR Therapeutics | $64.21 | $5B | -43.3% | 349.6% |
| BHC Bausch Health Companies | $9.12 | $3B | -70.9% | -26.1% |
| RETA Reata Pharmaceuticals, Inc. | $31.71 | $1B | -77.2% | 10.8% |
| PACB Pacific Biosciences of California | $5.09 | $1B | -80.5% | 46.3% |
Full Answer
Are CRISPR stocks a good investment?
There are good investments and there are great investments. CRISPR Therapeutics ( NASDAQ:CRSP) stock certainly qualifies as the latter. This is a company that, four years after it went public, has only been profitable for one year, yet its future is so promising that its stock is trading for 540% more than it did in 2016.
How to invest in CRISPR?
The Best CRISPR Companies to Invest In
- CRISPR companies forging the future. Several companies are using CRISPR to edit human genomes in an attempt to treat (and even cure) genetic diseases.
- 5 best CRISPR stocks to buy. Not every investor will want to buy CRISPR gene-editing stocks. ...
- Beam Therapeutics. ...
- CRISPR Therapeutics. ...
- Editas Medicine. ...
- Intellia Therapeutics. ...
- Verve Therapeutics. ...
What is CRSP stock?
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- MarketBeat: Week in Review 2/7 – 2/11
- Can Uber (NYSE: UBER) Get Back On Track?
- The Institutions Are Buying Newell Brands, Maybe You Should Too
- Western Digital Stock is Ready to Pick Up
- 3 Brawny International Stocks to Add to Your Portfolio
How do you use CRISPR?
- Production of an inhibitor may be made constant and at high concentration.
- Modifying the operator, or the represser, or or the inducer, to block the progress of RNA polymerase .
- Alternatively, RNA polymerase binding can be blocked
Can you buy CRISPR stock?
Learn how to easily invest in CRISPR Therapeutics stock. CRISPR Therapeutics AG is a biotechnology business based in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars.
Is CRISPR stock a good buy now?
There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock.
What was CRISPR IPO price?
$14.00 per share18, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share.
Who owns CRISPR stock?
Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedThe Vanguard Group, Inc.1.52%1,170,336T. Rowe Price Associates, Inc. (I...1.51%1,166,114Armistice Capital LLC1.33%1,024,000Bellevue Asset Management AG1.20%926,9056 more rows
Is CRISPR stock overvalued?
Many CRISPR gene editing stocks have been overvalued, although share prices have dropped quite a bit.
Is CRSP a buy or sell?
The consensus among 12 Wall Street analysts covering (NASDAQ: CRSP) stock is to Buy CRSP stock.
Is CRISPR available to the public?
The current trials using CRISPR-based treatments are still in early stages. That means that even if the treatments are safe and effective, they're likely still a few years away from FDA approval and being broadly available to patients.
Why has CRISPR stock gone down?
Rising research and development (R&D) expenses have led to expanding losses for CRISPR Therapeutics, and the relatively nascent state of the company's treatment catalog and pipeline means that the business is still posting minuscule revenue.
Is CRISPR public?
04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of its common shares at a public offering price of $22.75 per share, ...
How many shares of CRISPR are there?
CRISPR Therapeutics AGVolume1.47MShares Outstanding77.46MEPS (TTM)$3.60P/E Ratio (TTM)14.50Dividend YieldN/A7 more rows
What company developed CRISPR?
Ligandal: Establishing the CRISPR Delivery System Ligandal (@ligandal), a San Francisco-based company, has developed new technology which streamlines the in vivo delivery mechanisms for CRISPR, RNA, and other genetic tools.
Does Ark have CRISPR?
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 14,400 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) scooped up 45,500 shares. At Wednesday's closing price, this would have valued the sales at roughly $4.6 million altogether....Cathie Wood's ARK Invest Buys Nearly 60,000 Shares of CRISPR.FundARKGDirectionBuyTickerCRSPNameCRISPR THERAPEUTICSShares14,40022 more columns•Dec 30, 2021
Is CRISPR Therapeutics stock a Buy, Sell or Hold?
CRISPR Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 29 buy ratings, 10 hold ratings, and...
What was the 52-week low for CRISPR Therapeutics stock?
The low in the last 52 weeks of CRISPR Therapeutics stock was 42.60. According to the current price, CRISPR Therapeutics is 136.95% away from the 5...
What was the 52-week high for CRISPR Therapeutics stock?
The high in the last 52 weeks of CRISPR Therapeutics stock was 169.68. According to the current price, CRISPR Therapeutics is 34.38% away from the...
What are analysts forecasts for CRISPR Therapeutics stock?
The 39 analysts offering price forecasts for CRISPR Therapeutics have a median target of 121.41, with a high estimate of 187.00 and a low estimate...
What is CRISPR Therapeutics?
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
How many articles has The Fool written on CRISPR?
The Fool has written over 200 articles on CRISPR Therapeutics.
What would happen if the market crashed?
If the market crashes these companies could be insulated.
What is CRISPR Therapeutics?
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
What is the P/E ratio of CRISPR?
The P/E ratio of CRISPR Therapeutics is 16.82 , which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.69.
What is the CRISPR Therapeutics mailing address?
CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].
What is the CRSP symbol?
CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
Does CRISPR pay dividends?
CRISPR Therapeutics does not currently pay a dividend.
How to invest in CRISPR?
Invest in the CRISPR stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the gene editing industry, track how your stock performs to decide when it’s time to sell.
What is CRISPR Therapeutics?
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Can you buy fractional shares?
Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
Is CRISPR stock a risk?
Bottom line. While it’s possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest.
Steps To Buying Or Selling CRISPR Therapeutics Stocks and Shares
Decide how you want to buy, sell or trade CRISPR Therapeutics CRSP stocks and shares. Do you want to to trade in CRISPR Therapeutics CFD Stocks, Fractional CRISPR Therapeutics shares or traditional CRISPR Therapeutics Stocks.
Buy or Sell CRISPR Therapeutics (CRSP) Stock for 61.89 USD
The highest price CRISPR Therapeutics stock has been at in the last year is 175.44 USD and its lowest price the last year was 55.35 USD.
How To Buy Or Sell CRISPR Therapeutics CRSP Stocks & Shares
You can purchase CRISPR Therapeutics shares directly through a brokerage account or one of the various investment applications available. These systems allow you to buy, trade, and keep CRISPR Therapeutics stocks from the comfort of your own home or smartphone.
Choosing An CRISPR Therapeutics Stock Broker
When choosing a CRISPR Therapeutics stock broker, make sure you consider the variety of exchanges that the broker offers through which to buy and sell individual CRISPR Therapeutics stocks and securities, the commissions and fees charged by the broker for conducting trading in CRISPR Therapeutics, and what margin rates the broker offers.
Steps to Trading CRISPR Therapeutics CRSP Stocks & Shares
You've opted to purchase CRISPR Therapeutics CRSP stocks and shares. Let's explore what's in store for you before you can declare yourself an CRISPR Therapeutics CRSP stock shareholder. The procedure is same for any company's stock, and we'll use CRISPR Therapeutics CRSP as an example.
How To Buy Sell Or Trade CRISPR Therapeutics Stock Guide
When it comes to trading, risk is the potential that your CRISPR Therapeutics investment might fail to deliver any anticipated monetary gains. This could mean receiving lower returns than expected, or losing the original CRISPR Therapeutics investment itself.
CRISPR Therapeutics CRSP Trading Fees
some CRISPR Therapeutics stock brokers are currently offering low or no trading fees for trading CRISPR Therapeutics. There is also no account minimum, but there are a variety of promotional offers that you should be aware of before investing in CRISPR Therapeutics stock.
These CRISPR stocks could be big winners for patient investors
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
CRISPR companies forging the future
Several companies are using CRISPR to edit human genomes in an attempt to treat (and even cure) genetic diseases. Their therapies either use an ex vivo approach or an in vivo approach. With ex vivo therapies, genes are edited outside of the body.
5 best CRISPR stocks to buy
Not every investor will want to buy CRISPR gene-editing stocks. These stocks tend to be highly risky and volatile. However, for aggressive investors who aren't risk-averse, here are five of the best CRISPR stocks to consider:
Beam Therapeutics
Beam Therapeutics' base-editing approach enables the company to rewrite a single letter of the genome. While other CRISPR methods are similar to genetic scissors, base editing is more like a pencil with an eraser.
CRISPR Therapeutics
CRISPR Therapeutics has the most advanced pipeline among CRISPR-focused biotech stocks. The company and its partner, Vertex Pharmaceuticals ( NASDAQ:VRTX), hope to file for regulatory approvals in late 2022 of CTX001 for treating genetic blood disorders beta-thalassemia and sickle cell disease.
Editas Medicine
Editas Medicine is leading the way in using CRISPR to treat rare genetic eye diseases. The company reported preliminary results in September 2021 from a phase 1/2 study evaluating EDIT-101 in treating Leber congenital amaurosis 10 (LCA10).
Intellia Therapeutics
Intellia Therapeutics surged to the top spot among CRISPR stocks in 2021. The company and its partner, Regeneron ( NASDAQ:REGN), announced impressive interim results in June 2021 from a phase 1 study evaluating NTLA-2001 in treating rare genetic disease transthyretin (ATTR) amyloidosis.
What is CRISPR therapeutics?
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis.
Is CRISPR Therapeutics a US company?
CRISPR Therapeutics AG is a biotechnology business based in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. CRISPR Therapeutics employs 410 staff and has a trailing 12-month revenue of around 0.00.
Is CRISPR Therapeutics stock undervalued or overvalued?
Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Is it a good time to buy CRISPR Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
